Researchers at the Institut Pasteur and Inserm have developed a novel triple-therapy that reprograms how B cell cancers ...

JADE201 builds on clinical proof-of-concept for BAFF-R targeting, adding half-life extension technology to provide extended receptor occupancy with the goal of delivering deeper, more durable B cell ...

NX-1607 demonstrated on-target peripheral immune activation characteristic of an active immune-oncology agent with a novel immune checkpoint ...

DESTIN, Fla. — An increasing array of B-cell targeting approaches may aid clinicians in managing the cycles and flares of lupus, according to a speaker at the Congress of Clinical Rheumatology East ...

Please provide your email address to receive an email when new articles are posted on . A “complete eradication” of B cells with chimeric antigen receptor T-cell therapy is responsible for the ...

Provectus Biopharmaceuticals, Inc. ('Provectus” or the 'Company”) (OTCQB: PVCT) today announced the publication of independent preclinical research by Aru Narendran, MD, PhD and colleagues at the ...

This new article publication from Acta Pharmaceutica Sinica B, discusses how single-cell RNA sequencing reveals that Shen-Bai-Jie-Du decoction retards colorectal tumorigenesis by regulating the ...

By Shreoshree Chakrabarty: B-Cell Acute Lymphoblastic Leukemia (B-ALL) is a rare but aggressive form of leukemia that primarily impacts adults, unlike its more common pediatric counterpart. It ...